Skip to content

Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds

Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01417234
Enrollment
30
Registered
2011-08-16
Start date
2011-06-30
Completion date
2012-10-31
Last updated
2022-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Wound, Recent, Trauma-related Wound

Brief summary

The purpose of this study is to evaluate the efficacy of the Spiracur SNaP® Wound Care System for the treatment of acute trauma and acute surgical excision wounds. The secondary purpose will be to compare the prospective patients to retrospectively treated acute trauma wounds to further evaluate efficacy and safety.

Interventions

Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.

Sponsors

3M
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Trauma wound, pressure ulcer, post operative wound, colostomy take-down site, or other acute wound deemed appropriate by study investigator(s) as the source of the wound on any part of the body including head and neck, torso, and extremities * Wound \< 16 cm in greatest diameter * Subject ≥ 18 years of age * Exudate \< 25 ml/ day (estimate) * Female subjects of child-bearing potential must be willing to take a urine pregnancy test prior to starting study * Subject is willing and able to sign informed consent

Exclusion criteria

* Wound \> 45 days old * Wound-related cellulitis * Wound located in an area not amenable to forming an air-tight seal * Subject has untreated osteomyelitis * Subject is allergic to wound care products * Wound has exposed blood vessels not suitable for negative pressure therapy * Subject is pregnant * Subject is actively participating in other clinical trials that conflict with current study * Subject has fistulas

Design outcomes

Primary

MeasureTime frameDescription
Wound Closure12 weeksPercent of subjects with study wound deemed closed at 12 weeks 1 wound is studied per participant

Secondary

MeasureTime frameDescription
Percent Wound Size ChangeBaseline and 4 weeksPercent change in wound size from baseline to week 4 (Week 4 - baseline / baseline)

Countries

United States

Participant flow

Participants by arm

ArmCount
SNaP® Wound Care System
SNaP® Wound Care System: Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
30
Total30

Withdrawals & dropouts

PeriodReasonFG000
Overall StudySubject non-compliant3

Baseline characteristics

CharacteristicSNaP® Wound Care System
Age, Customized
Age
55 years
STANDARD_DEVIATION 11.94
Race/Ethnicity, Customized
Caucasian
12 Participants
Race/Ethnicity, Customized
Unknown
18 Participants
Region of Enrollment
United States
30 participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
14 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 30
other
Total, other adverse events
0 / 30
serious
Total, serious adverse events
0 / 30

Outcome results

Primary

Wound Closure

Percent of subjects with study wound deemed closed at 12 weeks 1 wound is studied per participant

Time frame: 12 weeks

Population: Per protocol population used for analysis. 3 subjects withdrew from study early due to non-compliance with study therapy and were not included in this analysis.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SNaP® Wound Care SystemWound Closure22 Participants
Secondary

Percent Wound Size Change

Percent change in wound size from baseline to week 4 (Week 4 - baseline / baseline)

Time frame: Baseline and 4 weeks

ArmMeasureValue (MEAN)Dispersion
SNaP® Wound Care SystemPercent Wound Size Change-41 percent changeStandard Deviation 0.43
Secondary

Percent Wound Size Change

Percent change in wound size from week 4 to week 8 (Week 8 - Week 4 / Week 4)

Time frame: 4 weeks and 8 weeks

ArmMeasureValue (MEAN)Dispersion
SNaP® Wound Care SystemPercent Wound Size Change-18.2 percent changeStandard Deviation 0.39
Secondary

Percent Wound Size Change

Percent change in wound size from week 8 to week 12 (12 Weeks - 8 weeks / 8 weeks)

Time frame: 8 weeks and 12 weeks

ArmMeasureValue (MEAN)Dispersion
SNaP® Wound Care SystemPercent Wound Size Change-3.6 percent changeStandard Deviation 0.11

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026